ArticleJournal of neuro-oncology2026
Clinical, radiographic, and neuropathologic characterization of peripherally hyperenhancing brain metastases: a novel radiographic entity.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSelect brain metastases display peripheral hyperenhancement at the tumor-brain interface, constituting a unique radiographic entity. However, the incidence, associated clinical characteristics, pathologic correlates, and longer-term outcomes associated with this phenomenon remain largely unknown. Here, we characterize peripherally hyperenhancing brain metastases to inform clinical management.
methodsWe identified 922 patients with 2790 newly-diagnosed brain metastases between 2009 and 2022 managed with brain-directed radiation at Brigham and Women's Hospital/Dana-Farber Cancer Institute. Peripheral hyperenhancement was defined as visualized contrast uptake at the periphery of the tumor exceeding background enhancement of the metastasis. Peripheral hyperenhancement was assessed at both per-patient and per-metastasis levels. Predictors and outcomes associated with peripherally hyperenhancing brain metastases were assessed using multivariable logistic and Fine-Gray models, respectively.
resultsIn total, 137 patients (15%) and 176 metastases (6%) demonstrated peripheral hyperenhancement. Pathologically, peripherally hyperenhancing metastases displayed tumor cells infiltrating brain parenchyma. Patients with peripheral hyperenhancement were more likely to present with neurologic symptoms (84% vs. 60%, p < 0.001) and seizures (20% vs. 12%, p = 0.008). Renal primaries (vs. the reference of non-small cell lung cancer, OR 2.54 [95% CI 1.19-5.45], p = 0.02) and larger metastasis size (OR 1.03 per 1 mm increase [95% CI 1.02-1.04], p < 0.001) were associated with peripheral hyperenhancement. Peripheral hyperenhancement was not associated with survival-based, recurrence-based, or other time-to-event outcomes after initial management.
conclusionPeripherally hyperenhancing brain metastases represent a distinct radiographic entity associated with renal primaries, edema, and neurologic symptomatology, with implications for surgical management and target delineation during stereotactic radiation. Definitive treatment seems to mitigate the aggressive nature of such tumors.
Indexed as
Identifiers
42640397What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.